2025
Proceedings of the National Cancer Institute Workshop on combining immunotherapy with radiotherapy: challenges and opportunities for clinical translation
Morris Z, Demaria S, Monjazeb A, Formenti S, Weichselbaum R, Welsh J, Enderling H, Schoenfeld J, Brody J, McGee H, Mondini M, Kent M, Young K, Galluzzi L, Karam S, Theelen W, Chang J, Huynh M, Daib A, Pitroda S, Chung C, Serre R, Grassberger C, Deng J, Sodji Q, Nguyen A, Patel R, Krebs S, Kalbasi A, Kerr C, Vanpouille-Box C, Vick L, Aguilera T, Ong I, Herrera F, Menon H, Smart D, Ahmed J, Gartrell R, Roland C, Fekrmandi F, Chakraborty B, Bent E, Berg T, Hutson A, Khleif S, Sikora A, Fong L. Proceedings of the National Cancer Institute Workshop on combining immunotherapy with radiotherapy: challenges and opportunities for clinical translation. The Lancet Oncology 2025, 26: e152-e170. PMID: 40049206, DOI: 10.1016/s1470-2045(24)00656-9.Peer-Reviewed Original ResearchConceptsAnti-tumor immune responseDelivery of radiotherapyTumor immune recognitionSelection of immunotherapyBiomarker-guided approachesNational Cancer Institute workshopClinical trial dataImmunotherapy combinationsClinical responseImprove patient outcomesPreclinical modelsPatient selectionRadiotherapyImmunotherapyClinical endpointsClinical dataClinical studiesImmune recognitionImmune responseImmune effectsAnimal studiesClinical translationPatient outcomesTrial dataNegative trialsComputational Nuclear Oncology Toward Precision Radiopharmaceutical Therapies: Current Tools, Techniques, and Uncharted Territories.
Yusufaly T, Roncali E, Brosch-Lenz J, Uribe C, Jha A, Currie G, Dutta J, El-Fakhri G, McMeekin H, Pandit-Taskar N, Schwartz J, Shi K, Strigari L, Zaidi H, Saboury B, Rahmim A. Computational Nuclear Oncology Toward Precision Radiopharmaceutical Therapies: Current Tools, Techniques, and Uncharted Territories. Journal Of Nuclear Medicine 2025, jnumed.124.267927. PMID: 39947910, DOI: 10.2967/jnumed.124.267927.Peer-Reviewed Original ResearchRadiopharmaceutical therapyImage-based dosimetryPrediction of doseInternal dosimetryPersonalized treatment plansMetastatic diseaseDosimetryNuclear oncologyClinical outcomesNuclear medicineClinical endpointsTreatment planningOncology communityDose responseEtiological mechanismsTargeted deliveryRadiobiologyRadiotherapyMalignancyRadiationLong-termTherapyPharmacotherapyDoseRadiopharmacokineticsParadoxical control of multifocal mammary oncogenesis by radiation therapy
Galluzzi L, Buqué A. Paradoxical control of multifocal mammary oncogenesis by radiation therapy. OncoImmunology 2025, 14: 2458886. PMID: 39873285, PMCID: PMC11776481, DOI: 10.1080/2162402x.2025.2458886.Peer-Reviewed Original ResearchPostoperative Radiotherapy ± Cetuximab for Intermediate-Risk Head and Neck Cancer.
Machtay M, Torres-Saavedra P, Thorstad W, Nguyen-Tân P, Siu L, Holsinger F, El-Naggar A, Chung C, Cmelak A, Burtness B, Bednarz G, Quon H, Breen S, Gwede C, Dicker A, Yao M, Jordan R, Dorth J, Lee N, Chan J, Dunlap N, Bar-Ad V, Stokes W, Chakravarti A, Sher D, Rao S, Harris J, Yom S, Le Q, Bar-Ad V, Bednarz G, Bowles D, Breen S, Burtness B, Chakravarti A, Chan J, Chung C, Cmelak A, Dicker A, Dorth J, Dunlap N, El-Naggar A, Gwede C, Harris J, Holsinger F, Jones C, Jordan R, Krempl G, Le Q, Lee N, Lominska C, Ma D, Machtay M, Mell L, Nguyen-Tan P, Quon H, Raben A, Rao S, Samuels S, Sher D, Siu L, Spencer S, Stokes W, Takiar V, Thorstad W, Torres-Saavedra P, Wilke C, Yao M, Yom S, Young M. Postoperative Radiotherapy ± Cetuximab for Intermediate-Risk Head and Neck Cancer. Journal Of Clinical Oncology 2025, jco2401829. PMID: 39841939, DOI: 10.1200/jco-24-01829.Peer-Reviewed Original ResearchDisease-free survivalOverall survivalToxicity ratesEpidermal growth factor receptor expressionGrowth factor receptor expressionHead and neck cancerHPV-negative diseaseIntermediate-risk cancerIntensity-modulated RTStratified log-rank testAcute toxicity ratesSecondary end pointsOral cavity cancerSquamous cell carcinomaLog-rank testHead and neckLong-term toxicityBenefit of RTFisher's exact testPostoperative RTCell carcinomaReceptor expressionNeck cancerOral cavityRadiotherapy
2024
3D gamma analysis between treatment plans for nominally beam‐matched medical linear accelerators using PyMedPhys
Guan F, Donahue W, Biggs S, Jennings M, Draeger E, Chen H, Wang Y, Nguyen N, Carlson D, Chen Z, Han D. 3D gamma analysis between treatment plans for nominally beam‐matched medical linear accelerators using PyMedPhys. Precision Radiation Oncology 2024, 8: 191-199. DOI: 10.1002/pro6.1247.Peer-Reviewed Original ResearchGamma analysisGamma indexEvaluation of treatment plansPlanned dose distributionMedical linear acceleratorPass rateEfficient treatment deliveryMedian pass rateDose distributionTreatment planningLinacLinear acceleratorCalculated doseTreatment deliveryConformal radiotherapyOriginal planRadiation therapyPatient transferDisease sitesIn-house scriptsBeam modelPatientsBeamRadiotherapyAccelerationGold-siRNA supraclusters enhance the anti-tumor immune response of stereotactic ablative radiotherapy at primary and metastatic tumors
Jiang Y, Cao H, Deng H, Guan L, Langthasa J, Colburg D, Melemenidis S, Cotton R, Aleman J, Wang X, Graves E, Kalbasi A, Pu K, Rao J, Le Q. Gold-siRNA supraclusters enhance the anti-tumor immune response of stereotactic ablative radiotherapy at primary and metastatic tumors. Nature Biotechnology 2024, 1-14. PMID: 39448881, DOI: 10.1038/s41587-024-02448-0.Peer-Reviewed Original ResearchStereotactic ablative radiotherapyAnti-tumor immune responseSmall interfering RNAAblative radiotherapyMetastatic tumorsEffect of stereotactic ablative radiotherapyModel of head and neck cancerHead and neck cancerImmunosuppressive cell populationsPD-1 inhibitorsSmall interfering RNA complexesPD-1Primary tumorImmunotherapeutic effectsNeck cancerGranzyme BGal-1Mouse modelPassive deliveryTumorReduced toxicityCell populationsRadiotherapyRadiosensitivityRenal filtration thresholdRadiomics-driven personalized radiotherapy for primary and recurrent tumors: A general review with a focus on reirradiation
Beddok A, Orlhac F, Rozenblum L, Calugaru V, Créhange G, Dercle L, Nioche C, Thariat J, Marin T, El Fakhri G, Buvat I. Radiomics-driven personalized radiotherapy for primary and recurrent tumors: A general review with a focus on reirradiation. Cancer/Radiothérapie 2024, 28: 597-602. PMID: 39406602, DOI: 10.1016/j.canrad.2024.09.002.Peer-Reviewed Original ResearchPersonalized radiotherapyTumor localizationTreatment planningMedian AUCImaging modalitiesRisk of recurrenceHead and neckImprove treatment precisionPredicting clinical outcomesOptimal treatment planQuantitative imaging biomarkersRecurrent tumorsApplication of radiomicsRecurrent cancerClinical radiotherapyExternal validationClinical outcomesRadiotherapyReirradiationLack of external validationMEDLINE searchTreatment precisionImaging biomarkersImaging protocolTumorImpact of Synthetic PET Evaluation prior to PET-Guided Functional Modeling in Optimizing Patient Selection for Biology-Guided Radiotherapy
Hicks D, Chen H, Kim J, Tressel L, Wallington D, Becht K, Johung K, Young M, Feghali K, de Jong D, Chen Z, Carlson D, Park H. Impact of Synthetic PET Evaluation prior to PET-Guided Functional Modeling in Optimizing Patient Selection for Biology-Guided Radiotherapy. International Journal Of Radiation Oncology • Biology • Physics 2024, 120: s162-s163. DOI: 10.1016/j.ijrobp.2024.07.2188.Peer-Reviewed Original ResearchPlanning target volumeInternal target volumeBiology-guided radiotherapyStereotactic body radiotherapyGross tumor volumeTarget volumeCT simulationOptimal patient selectionPET evaluationStereotactic body radiotherapy planLung target volumesPatient selectionPTV edgesLung casesBgRTPET-CTTumor sizeTumor volumeRadiotherapyCase 2PET dataLungActivity concentrationsPatientsConsistent with resultsAmerican Radium Society Appropriate Use Criteria on Cardiac Toxicity Prevention and Management After Thoracic Radiotherapy
Amini A, Zaha V, Hamad E, Woodard P, Rimner A, Chang J, Chun S, Donington J, Edelman M, Gubens M, Higgins K, Iyengar P, Juloori A, Movsas B, Ning M, Park H, Rodrigues G, Wolf A, Simone C. American Radium Society Appropriate Use Criteria on Cardiac Toxicity Prevention and Management After Thoracic Radiotherapy. Journal Of Thoracic Oncology 2024, 19: 1654-1667. PMID: 39313150, PMCID: PMC11665043, DOI: 10.1016/j.jtho.2024.09.1433.Peer-Reviewed Original ResearchConceptsCardiac toxicityCardiac comorbiditiesThoracic radiotherapyToxicity preventionAmerican Radium Society Appropriate Use CriteriaAbsence of cardiovascular risk factorsLow riskHigh riskMultidisciplinary consensus guidelinesTreatment-related risksAppropriate Use CriteriaCardiovascular risk factorsVariants of patientsThoracic malignanciesModified Delphi methodologyCardiac substructuresConsensus guidelinesRadiotherapyRisk factorsCardiac imagingComorbiditiesDose exposurePatientsSystematic reviewThoracicTert-expressing cells contribute to salivary gland homeostasis and tissue regeneration after radiation therapy
Guan L, Viswanathan V, Jiang Y, Vijayakumar S, Cao H, Zhao J, Colburg D, Neuhöfer P, Zhang Y, Wang J, Xu Y, Laseinde E, Hildebrand R, Rahman M, Frock R, Kong C, Beachy P, Artandi S, Le Q. Tert-expressing cells contribute to salivary gland homeostasis and tissue regeneration after radiation therapy. Genes & Development 2024, 38: 569-582. PMID: 38997156, PMCID: PMC11293384, DOI: 10.1101/gad.351577.124.Peer-Reviewed Original ResearchConceptsSubmandibular glandSalivary gland homeostasisProgenitor cellsGland homeostasisResponse to radiotherapyAdult submandibular glandCell survivalSalivary gland regenerationSelf-renewal capacityEnhanced proliferative activityRadiation therapyDuctal regionsRadiotherapyModulate cell survivalTelomerase-expressingGland regenerationProliferative activityMouse strainsTERT expressionCreERT2 recombinaseSalivary gland biologyRadiation exposureTERT locusIn vitro cultureCell populationsCharacterization of time toxicity in older patients with metastatic breast cancer
Atre S, Soulos P, Kuderer N, Gross C, Baum L, Dinan M, Lustberg M. Characterization of time toxicity in older patients with metastatic breast cancer. Breast Cancer Research And Treatment 2024, 207: 541-550. PMID: 38816556, DOI: 10.1007/s10549-024-07379-7.Peer-Reviewed Original ResearchMetastatic breast cancerBone-modifying agentsComorbid medical conditionsOlder patientsBreast cancerRetrospective cohort studySEER-Medicare databaseTreatment typeCancer treatment modalityTreatment modalitiesSEER-MedicareCohort studyUnadjusted analysisPatientsAge-related impactCancer treatmentComorbiditiesDay patientsCancerRadiotherapyOlder ageMedical conditionsToxicityTreatmentSociodemographic factorsPerivascular NOTCH3+ Stem Cells Drive Meningioma Tumorigenesis and Resistance to Radiotherapy.
Choudhury A, Cady M, Lucas C, Najem H, Phillips J, Palikuqi B, Zakimi N, Joseph T, Birrueta J, Chen W, Oberheim Bush N, Hervey-Jumper S, Klein O, Toedebusch C, Horbinski C, Magill S, Bhaduri A, Perry A, Dickinson P, Heimberger A, Ashworth A, Crouch E, Raleigh D. Perivascular NOTCH3+ Stem Cells Drive Meningioma Tumorigenesis and Resistance to Radiotherapy. Cancer Discovery 2024, 14: 1823-1837. PMID: 38742767, PMCID: PMC11452293, DOI: 10.1158/2159-8290.cd-23-1459.Peer-Reviewed Original ResearchConceptsResistance to radiotherapyMeningioma tumorigenesisSystemic therapyTreating meningiomasStem cellsGenetically engineered mouse modelsTumor-initiating capacityHigh-grade meningiomasReduced tumor growthPrimary intracranial tumorsMeningioma growthImproved survivalIntracranial tumorsRadiotherapyTherapeutic vulnerabilitiesTumor growthMeningiomasMouse modelSingle-cell transcriptomicsLineage tracingNotch3TumorigenesisCell proliferationReduced survivalCell typesRadiation therapy for triple-negative breast cancer: from molecular insights to clinical perspectives
Kim J, Fahmy V, Haffty B. Radiation therapy for triple-negative breast cancer: from molecular insights to clinical perspectives. Expert Review Of Anticancer Therapy 2024, 24: 211-217. PMID: 38502143, DOI: 10.1080/14737140.2024.2333320.Peer-Reviewed Original ResearchTriple-negative breast cancerPoly (ADP-ribose) polymeraseLocoregional controlRadiation therapyBreast cancerImpact of post-mastectomy radiation therapyPost-mastectomy radiation therapyEffects of radiotherapySynergistic effects of radiotherapyPersonalized treatment approachesImproved survival ratesIntegration of radiomicsImmunotherapy combinationsBRCA1/2 mutationsRadiotherapy responseOvercome radioresistanceTargeted radiosensitizationImprove patient outcomesRadiosensitizing strategiesNovel radiosensitizersTarget biological pathwaysTreatment strategiesTreatment outcomesMolecular profilingRadiotherapyExecutive summary of the American Radium Society appropriate use criteria for brain metastases in epidermal growth factor receptor mutated-mutated and ALK-fusion non-small cell lung cancer
Nagpal S, Milano M, Chiang V, Soltys S, Brackett A, Halasz L, Garg A, Sahgal A, Ahluwalia M, Tom M, Palmer J, Knisely J, Chao S, Gephart M, Wang T, Lo S, Chang E. Executive summary of the American Radium Society appropriate use criteria for brain metastases in epidermal growth factor receptor mutated-mutated and ALK-fusion non-small cell lung cancer. Neuro-Oncology 2024, 26: 1195-1212. PMID: 38459978, PMCID: PMC11226873, DOI: 10.1093/neuonc/noae041.Peer-Reviewed Original ResearchNon-small cell lung cancerTyrosine kinase inhibitorsCell lung cancerCentral nervous systemAmerican Radium SocietyALK-fusionBrain metastasesAmerican Radium Society Appropriate Use CriteriaLung cancerSequence of tyrosine kinase inhibitorsALK tyrosine kinase inhibitorsTreatment of brain metastasesEGFR tyrosine kinase inhibitorsWhole-brain RTEpidermal growth factor receptorGrowth factor receptorAppropriate Use CriteriaBrain RTEGFR-mutantRadiotherapyTreatment optionsFactor receptorKinase inhibitorsNervous systemLiterature searchO 09 Radiotherapy utilization and outcomes from a contemporary study of brentuximab vedotin with chemotherapy in pediatric high-risk Hodgkin lymphoma
Hoppe B, Castellino S, Pei Q, Charpentier A, Mailhot-Vega R, Roberts K, Parikh R, Flampouri S, Kelly K, Hodgson D. O 09 Radiotherapy utilization and outcomes from a contemporary study of brentuximab vedotin with chemotherapy in pediatric high-risk Hodgkin lymphoma. International Journal Of Particle Therapy 2024, 11: 100032. DOI: 10.1016/j.ijpt.2024.100032.Peer-Reviewed Original ResearchThe Role of Targeted Radiation Therapy in the Treatment of Renal Cell Carcinoma
Lee A, Runcie K, Yu J. The Role of Targeted Radiation Therapy in the Treatment of Renal Cell Carcinoma. Kidney Cancer 2024, 8: 45-50. DOI: 10.3233/kca-230020.Peer-Reviewed Original ResearchStereotactic body radiotherapyTreatment of renal cell carcinomaRenal cell carcinomaCell carcinomaCombination of stereotactic body radiotherapyUse of stereotactic body radiotherapyNovel systemic agentsTargeted radiation therapyTreatment of RCCRadiation therapySystemic agentsCarcinomaTreatmentRCCRadiotherapyRadiation technologyIncreased useTherapyClinical acceptability of automatically generated lymph node levels and structures of deglutition and mastication for head and neck radiation therapy
Maroongroge S, Mohamed A, Nguyen C, De la Vega J, Frank S, Garden A, Gunn B, Lee A, Mayo L, Moreno A, Morrison W, Phan J, Spiotto M, Court L, Fuller C, Rosenthal D, Netherton T. Clinical acceptability of automatically generated lymph node levels and structures of deglutition and mastication for head and neck radiation therapy. Physics And Imaging In Radiation Oncology 2024, 29: 100540. PMID: 38356692, PMCID: PMC10864833, DOI: 10.1016/j.phro.2024.100540.Peer-Reviewed Original ResearchLymph node levelsAI contoursClinical acceptanceSwallowing structuresComputed tomographyHead and neck radiotherapy patientsHead and neckMedian Dice similarity coefficientLevels I-VDice similarity coefficientRadiotherapy patientsCT scanManual contouringLymphComplex anatomyCT imagesCohortI-VPatientsChewingSimilarity coefficientAnatomyRadiotherapyHeadNode level
2023
PACS-Integrated Tools for Peritumoral Edema Volumetrics Provide Additional Information to RANO-BM-Based Assessment of Lung Cancer Brain Metastases after Stereotactic Radiotherapy: A Pilot Study
Kaur M, Petersen G, Jekel L, von Reppert M, Varghese S, de Oliveira Santo I, Avesta A, Aneja S, Omuro A, Chiang V, Aboian M. PACS-Integrated Tools for Peritumoral Edema Volumetrics Provide Additional Information to RANO-BM-Based Assessment of Lung Cancer Brain Metastases after Stereotactic Radiotherapy: A Pilot Study. Cancers 2023, 15: 4822. PMID: 37835516, PMCID: PMC10571649, DOI: 10.3390/cancers15194822.Peer-Reviewed Original ResearchPost-SRTStereotactic radiotherapyLung cancer brain metastasesCancer brain metastasesPost-contrast T1-weighted imagesSignificant clinical symptomsContrast-enhancing tumorT1-weighted imagesCritical additional informationEdema changesBrain metastasesClinical symptomsCare treatmentHyperintense volumeEdema assessmentLesion changesLesion sizeEdemaDifferent timepointsPilot studyRadiotherapyLesionsVolumetric changesAdditional informationMETSNationwide changes in radiation oncology travel and location of care before and during the COVID-19 pandemic
De Leo A, Giap F, Culbert M, Drescher N, Brisson R, Cassidy V, Augustin E, Casper A, Horowitz D, Cheng S, Yu J. Nationwide changes in radiation oncology travel and location of care before and during the COVID-19 pandemic. Radiation Oncology Journal 2023, 41: 108-119. PMID: 37403353, PMCID: PMC10326508, DOI: 10.3857/roj.2023.00164.Peer-Reviewed Original ResearchProportion of patientsRadiation treatmentNational Cancer DatabaseRadiation therapy treatmentCancer DatabaseAnalyzed patientsClinical variablesCoronavirus diseaseRadiotherapyPatientsTherapy treatmentCancer sitesCancerDestination facilityVulnerable to coronavirus diseaseTreatmentMean distanceLocation of careCoordinated careTransport barrierMedical careCareProportionNationwide changesHospitalGenomic and Transcriptomic Predictors of Response from Stereotactic Body Radiation Therapy in Patients with Oligoprogressive Renal Cell Carcinoma
Zengin Z, Govindarajan A, Salgia N, Sayegh N, Tripathi N, Muddasani R, Chehrazi-Raffle A, Feng M, Mercier B, Ladbury C, Hao C, Salgia S, Chawla N, Meza L, Malhotra J, Dizman N, Hsu J, Castro D, Barragan-Carrillo R, Ebrahimi H, Philip E, Chang M, Zhang J, Byron S, Lyou Y, Dorff T, Pal S, Dandapani S. Genomic and Transcriptomic Predictors of Response from Stereotactic Body Radiation Therapy in Patients with Oligoprogressive Renal Cell Carcinoma. European Urology Oncology 2023, 6: 447-450. PMID: 36609061, DOI: 10.1016/j.euo.2022.11.006.Peer-Reviewed Original ResearchConceptsMetastatic renal cell carcinomaStereotactic body radiation therapyRenal cell carcinomaBody radiation therapyCell carcinomaRadiation therapyClear cell renal cell carcinomaFirst-line treatmentCell renal cell carcinomaStereotactic body radiotherapyKidney cancer patientsOligoprogressive diseaseSystemic treatmentReactive oxygen species pathwayBody radiotherapyCancer patientsTreatment selectionPatientsTreatment changesOxygen species pathwayRadiation treatmentCarcinomaCell proliferationPotential roleRadiotherapy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply